These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19182452)

  • 41. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.
    Niemi M; Arnold KA; Backman JT; Pasanen MK; Gödtel-Armbrust U; Wojnowski L; Zanger UM; Neuvonen PJ; Eichelbaum M; Kivistö KT; Lang T
    Pharmacogenet Genomics; 2006 Nov; 16(11):801-8. PubMed ID: 17047488
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
    Schneck DW; Birmingham BK; Zalikowski JA; Mitchell PD; Wang Y; Martin PD; Lasseter KC; Brown CD; Windass AS; Raza A
    Clin Pharmacol Ther; 2004 May; 75(5):455-63. PubMed ID: 15116058
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin.
    Aquilante CL; Kiser JJ; Anderson PL; Christians U; Kosmiski LA; Daily EB; Hoffman KL; Hopley CW; Predhomme JA; Schniedewind B; Sidhom MS
    J Clin Pharmacol; 2012 Nov; 52(11):1725-38. PubMed ID: 22174437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.
    Danik JS; Chasman DI; MacFadyen JG; Nyberg F; Barratt BJ; Ridker PM
    Am Heart J; 2013 Jun; 165(6):1008-14. PubMed ID: 23708174
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Understanding the interplay of drug transporters involved in the disposition of rosuvastatin in the isolated perfused rat liver using a physiologically-based pharmacokinetic model.
    Hobbs M; Parker C; Birch H; Kenworthy K
    Xenobiotica; 2012 Apr; 42(4):327-38. PubMed ID: 22035568
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of OATP transporters in the disposition of drugs.
    Niemi M
    Pharmacogenomics; 2007 Jul; 8(7):787-802. PubMed ID: 18240907
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
    Bailey KM; Romaine SP; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; McCormack T; Whitehead A; Flather MD; Samani NJ; Nixon J; Hall AS; Balmforth AJ;
    Circ Cardiovasc Genet; 2010 Jun; 3(3):276-85. PubMed ID: 20207952
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Organic Cation Transporter 1 Is Responsible for Hepatocellular Uptake of the Tyrosine Kinase Inhibitor Pazopanib.
    Ellawatty WEA; Masuo Y; Fujita KI; Yamazaki E; Ishida H; Arakawa H; Nakamichi N; Abdelwahed R; Sasaki Y; Kato Y
    Drug Metab Dispos; 2018 Jan; 46(1):33-40. PubMed ID: 29089306
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic Information on SLCO1B1 and ABCC2 polymorphisms.
    Ide T; Sasaki T; Maeda K; Higuchi S; Sugiyama Y; Ieiri I
    J Clin Pharmacol; 2009 Nov; 49(11):1309-17. PubMed ID: 19776292
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Murine Oatp1a/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure.
    Iusuf D; van Esch A; Hobbs M; Taylor M; Kenworthy KE; van de Steeg E; Wagenaar E; Schinkel AH
    Mol Pharmacol; 2013 May; 83(5):919-29. PubMed ID: 23429889
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
    Niemi M; Pasanen MK; Neuvonen PJ
    Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Marked differences in frequencies of statin therapy relevant SLCO1B1 variants and haplotypes between Roma and Hungarian populations.
    Nagy A; Sipeky C; Szalai R; Melegh BI; Matyas P; Ganczer A; Toth K; Melegh B
    BMC Genet; 2015 Sep; 16():108. PubMed ID: 26334733
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Functional characterization for polymorphic organic anion transporting polypeptides (OATP/SLCO1B1, 1B3, 2B1) of monkeys recombinantly expressed with various OATP probes.
    Takahashi T; Uno Y; Yamazaki H; Kume T
    Biopharm Drug Dispos; 2019 Feb; 40(2):62-69. PubMed ID: 30652318
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy.
    Ieiri I; Takane H; Hirota T; Otsubo K; Higuchi S
    Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):651-74. PubMed ID: 17014387
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of hepatic uptake transporters by flavonoids.
    Mandery K; Balk B; Bujok K; Schmidt I; Fromm MF; Glaeser H
    Eur J Pharm Sci; 2012 May; 46(1-2):79-85. PubMed ID: 22394605
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin.
    Nezasa K; Higaki K; Takeuchi M; Nakano M; Koike M
    Xenobiotica; 2003 Apr; 33(4):379-88. PubMed ID: 12745873
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin.
    Windass AS; Lowes S; Wang Y; Brown CD
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1221-7. PubMed ID: 17585018
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin.
    Nezasa K; Higaki K; Matsumura T; Inazawa K; Hasegawa H; Nakano M; Koike M
    Drug Metab Dispos; 2002 Nov; 30(11):1158-63. PubMed ID: 12386119
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
    Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
    Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15.
    Deng JW; Song IS; Shin HJ; Yeo CW; Cho DY; Shon JH; Shin JG
    Pharmacogenet Genomics; 2008 May; 18(5):424-33. PubMed ID: 18408565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.